Alcoholic Hepatitis Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Alcoholic Hepatitis Treatment Market Trends and Insights

Rising Alcohol-Associated Liver Disease Burden

The growing burden of alcohol-related liver disease enlarges the patient pool for the alcoholic hepatitis treatment market. The rising prevalence of alcohol use disorder across the globe is boosting the demand and market growth. According to the American Liver Foundation, alcohol-associated liver disease (ALD) accounted for 5.1% of the global burden of disease and injury. This change complicates treatment development because earlier studies often enrolled predominantly male populations. The projected economic impact of alcohol-related liver disease in the United States could double by 2040 without intervention, which supports continued demand for prevention, hospital care, and treatment pathways.^{[1]A. K. Singal et al., “Alcohol-Associated Liver Disease Global Epidemiology,” Hepatology, lww.com}

Increasing Clinical Investment in Disease-Modifying Therapies

Clinical investment is widening the development pipeline for the alcoholic hepatitis treatment market. The Phase 3 LCAH3141 study of larsucosterol is recruiting 350 participants with alcohol-associated hepatitis, making it the most advanced registrational program.^{[2]ClinicalTrials.gov, “Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-Associated Hepatitis,” ClinicalTrials.gov, clinicaltrials.gov} The FDA has agreed that one successful pivotal study could support a New Drug Application for larsucosterol, which reduces the usual requirement for two positive trials. The candidate has FDA Breakthrough Therapy and Fast Track designations, which can support a more efficient review process.^{[3]Bausch Health Companies Inc., “Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-Stage Liver Disease Portfolio,” Bausch Health Investor Relations} Aldeyra Therapeutics reported statistically significant MELD score improvement with ADX-629 in October 2025, adding another mechanism to the clinical pipeline. 

Guideline-Based Severity Scoring and Treatment Adoption

Guideline-based assessment gives clinicians a more consistent basis for selecting patients in the alcoholic hepatitis treatment market. The AASLD guidance uses severity measures such as the Maddrey Discriminant Function and MELD score when clinicians assess alcohol-associated liver disease.^{[4]American Association for the Study of Liver Diseases, “Alcohol-Associated Liver Disease Practice Guidelines for Assessment, Severity Classification, and Clinical Management,” American Association for the Study of Liver Diseases, aasld.org} The MDF scores of 32 or higher and MELD scores of 21 to 30 were the treatment thresholds for severe disease. These measures help hospitals identify patients who may need pharmacological treatment, intensive observation, and referral to specialized services. The approach supports near-term use of corticosteroids and could simplify adoption decisions when new treatments become available. It can also inform formulary and reimbursement discussions when health systems consider evidence-based treatment pathways.

Expansion of Hospital-Based Severe Disease Management

Hospital-based care is a direct support for the alcoholic hepatitis treatment market because severe disease requires close inpatient supervision. Hospitals held 56.78% of the end-user segment in 2025, reflecting the need for parenteral treatment, infection surveillance, nutrition support, and daily clinical monitoring. Tertiary centers in the United States, Germany, and France have expanded access to intensive hepatology care. The PROCORNAC Phase 3 study, started in May 2026 at University Hospital Lille, is enrolling 477 patients to examine prolonged corticosteroid treatment and N-acetylcysteine combinations. The NIAAA-funded ITAALD study, which began in January 2026, is evaluating integrated treatment for severe alcoholic hepatitis and alcohol use disorder. These programs reinforce the role of hospitals as the setting where future treatment protocols can be introduced.

Absence of an Approved Disease-Modifying Therapy

The lack of an approved disease-modifying therapy remains the main constraint on the alcoholic hepatitis treatment market. Clinicians rely on off-label corticosteroids and supportive care because neither the FDA nor the EMA has approved a specific therapy for alcohol-associated hepatitis. This limits structured commercialization and makes reimbursement less predictable, especially in price-sensitive health systems. Health technology assessment bodies in Europe and Asia-Pacific also need strong comparative data before supporting off-label treatment at scale. Intercept Pharmaceuticals ended the Phase 2a FRESH study of INT-787 in March 2026 after finding no clear evidence of potential benefit. The result shows why durable clinical evidence is necessary before the alcoholic hepatitis treatment market can move beyond its current care model.

Limited Durability and Infection Risk of Corticosteroids

Corticosteroids remain widely used, but their clinical limits restrain the alcoholic hepatitis treatment market. Prednisolone at 40 mg per day for 28 days was associated with 30.00% 90-day mortality among treated patients, and bacterial and fungal infection risk remains an important concern. A randomized Phase 2 study of canakinumab found no improvement in biochemical or clinical outcomes compared with placebo in severe alcohol-related hepatitis. Combination regimens must therefore manage infection risk carefully, particularly in patients with substantial immunosuppression. These limitations continue to create a need for treatment options with better durability and safety.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Treatment Type: Pharmacological Therapy Anchors Revenue While Cell Therapy Accelerates

Pharmacological therapy held 73.23% of the alcoholic hepatitis treatment market share in 2025. The segment remains central because corticosteroid-based protocols are established in hospital practice and alternative therapies are not yet available at scale. Nutritional and supportive care supplies a stable base through enteral nutrition and zinc supplementation. 

Stem cell therapy is forecast to grow at a 12.34% CAGR from 2026 to 2031. This treatment type has drawn interest from mesenchymal stem cell programs that have reported safety findings and early efficacy signals in alcohol-related liver disease. A 2025 real-world study reported an adjusted hazard ratio of 0.14 for 5-year mortality after bone marrow-derived mesenchymal stem cell transplantation in matched cohorts with decompensated liver cirrhosis. 

By Drug Class: Corticosteroids Lead, Monoclonal Antibodies Reshape the Competitive Calculus

Corticosteroids held 38.34% of the alcoholic hepatitis treatment market share in 2025. Prednisolone remains the main drug in established treatment protocols for patients meeting severe-disease criteria. Hemorheologic agents, including pentoxifylline, have seen lower use after evidence questioned their benefit beyond corticosteroids alone. Antioxidants and hepatoprotective agents retain an adjunct role, particularly N-acetylcysteine in the PROCORNAC study. 

Monoclonal antibodies are forecast to expand at a 13.42% CAGR through 2031. Programs in this class include agents that target IL-1, TNF, fibrosis pathways, the gut-liver axis, and epigenetic dysregulation. The commercial outlook remains uncertain because canakinumab did not improve clinical or biochemical outcomes in a Phase 2 study. 

By Disease Type: Acute Presentation Dominates Volume and Sets the Innovation Agenda

Acute alcoholic hepatitis accounted for 78.34% of the disease-type segment in 2025. It was also reported as the fastest-growing disease-type sub-segment, with a 8.78% CAGR from 2026 to 2031. Acute episodes are the main point for clinical intervention because patients often require hospital treatment and are eligible for therapeutic trials. Severe cases are typically defined using measures such as MDF scores of 32 or higher or MELD scores of 21 to 30. This defined clinical profile helps investigators enroll patients and assess treatment outcomes consistently. As a result, acute disease remains the primary focus for commercial development in the alcoholic hepatitis treatment market.

Chronic alcoholic hepatitis generates demand through ongoing alcohol use disorder treatment, hepatoprotective medicines, and nutrition programs. It does not carry the same immediate inpatient urgency as acute disease, which limits high-value hospitalization spending. A June 2026 natural-history study reported a high incidence of combined liver and alcohol-use events within 6 months of an alcohol-associated hepatitis presentation. 

By Disease Severity: Severe AH Anchors the Market and Drives All Major Pipeline Investment

Severe alcoholic hepatitis held 50.23% of the alcoholic hepatitis treatment market size in 2025. It is also forecast to grow at an 8.12% CAGR through 2031. Severe disease attracts most treatment activity because its mortality risk and hospital burden make pharmacological intervention more likely. The larsucosterol Phase 3 program uses MELD scores of 21 to 30 in its study design. 

Mild and moderate alcoholic hepatitis together account for a significant share due to disease burden. These patients receive less targeted pharmacological investment because no well-validated treatment protocol exists beyond lifestyle management and nutritional support. The category could support outpatient administration and retail pharmacy use if a medicine shows benefit in non-severe disease. Earlier intervention may also allow clinical teams to manage disease before severe complications require intensive inpatient treatment. 

By Route of Administration: Oral Dominates, Parenteral Tracks the Severity Shift

Oral treatment held 68.36% of the route-of-administration segment in 2025. This reflects use of prednisolone, pentoxifylline, naltrexone, and acamprosate in current care protocols. Oral products can support treatment during hospital care and after discharge. They are familiar to clinicians and easier to dispense than therapies requiring infusion. Oral treatment also fits the growth of alcohol use disorder management in outpatient settings. These features maintain its leading place in the alcoholic hepatitis treatment market.

Parenteral treatment is forecast to grow at an 8.56% CAGR through 2031. Intravenous N-acetylcysteine, parenteral nutrition, and investigational medicines support this growth. Larsucosterol is administered as a single intravenous infusion on day 1 in its Phase 3 protocol. 

By End User: Hospitals Sustain the Base, Private Treatment Centers Emerge as Growth Vectors

Hospitals held 56.78% of the end-user segment in 2025. The inpatient setting is important because patients with severe alcoholic hepatitis may require parenteral therapy, infection monitoring, nutrition support, and frequent clinical assessment. Hospitals also provide access to hepatology specialists and transplant referral pathways. Specialty liver clinics and transplant centers serve patients who need focused follow-up or advanced treatment decisions.

Private treatment centers are forecast to grow at an 8.12% CAGR through 2031. Their growth reflects a shift in moderate-severity care and post-discharge alcohol use disorder treatment toward outpatient hepatology services. The ITAALD study is testing an integrated care model for alcohol-associated hepatitis and alcohol use disorder. 

By Distribution Channel: Hospital Pharmacies Dominant, Online Growth Signals Chronic Care Expansion

Hospital pharmacies accounted for 62.34% of the distribution-channel segment in 2025. Their leading position follows the inpatient treatment profile of severe alcoholic hepatitis and the need for parenteral administration. Hospital pharmacies can coordinate corticosteroids, intravenous medicines, nutrition-related products, and discharge planning. 

Online pharmacies are forecast to grow at a 10.98% CAGR through 2031. This growth is linked to alcohol use disorder medicines, including naltrexone and acamprosate, which can be supplied with telehealth prescribing in the United States and Western Europe. Retail pharmacies serve patients between hospital discharge and specialty follow-up, including those receiving oral treatment or nutrition supplements. These channels can help maintain access after discharge, but they do not replace the hospital pharmacy role for acute and infusion-based care. 

Geography Analysis

North America held 42.34% of the alcoholic hepatitis treatment market size in 2025. The United States supports this position through an estimated 164,000 annual hospital admissions for alcohol-associated hepatitis. The region has a favorable development setting because larsucosterol has an FDA Breakthrough Therapy Designation and is being studied in a U.S.-focused regulatory pathway. 

Europe is the second-largest regional block in the supply of material, led by Germany, France, the United Kingdom, and Italy. EASL-aligned clinical practice gives health systems a consistent framework for identifying and managing severe disease. University Hospital Lille began the PROCORNAC Phase 3 study in May 2026, showing the strength of Europe’s academic trial infrastructure. 

Asia-Pacific is forecast to grow at an 11.36% CAGR through 2031, the fastest regional rate in the alcoholic hepatitis treatment market. China and India are important opportunities because alcohol use disorder prevalence is rising, and hospital hepatology capacity is improving. Central Asia had the highest global incidence and death rates for alcohol-related liver disease.